Astellas Pharma News
Most Popular Astellas Pharma Story
Astellas makes $3.5B hostile bid for OSI
Astellas Pharma announced today that it has made a $3.5 billion hostile bid to acquire OSI Pharmaceuticals, which is developing molecular targeted therapies for oncology, diabetes and obesity. The... Read more...
Latest Headlines
- March 17, 2010
- March 16, 2010
- March 2, 2010
- March 1, 2010
- February 24, 2010
- December 18, 2009
- December 14, 2009
- November 10, 2009
- October 27, 2009
- September 14, 2009
- August 21, 2009
- June 22, 2009
- March 16, 2009
- March 3, 2009
- February 27, 2009
- February 23, 2009
- February 20, 2009
- January 28, 2009
- January 27, 2009
- September 19, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
